Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial.

Br J Dermatol · 2022 · PMC9298328 · PMID 34289086

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Patients in the difamilast 0·3% and difamilast 1% groups also showed highly significant success rates in IGA score compared with the vehicle group at weeks 1 and 2 (Figure 2 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.